Annual report
3840.TEDINET S100UCIM
Period2022-04-01 → 2023-03-31
Filed2024-09-11
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100RAZA.
Key figures · 134
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥220m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | −¥682m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥224m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥737m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥538m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥873m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5m | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥253m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥743m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥256m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥746m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥538m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥778m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥157m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥256m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥746m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.1bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.2bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥2.7bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥351m | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥802m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥470m | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥673m | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥743m | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥1.5bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥173m | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥345m | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥173m | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥345m | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥206m | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥252m | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥822m | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥352m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥836m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥502m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥346m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥210m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥114m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥24m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥2m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥248m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥517m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥281m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥999m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥454m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥472m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥145m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-5.46 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-20.95 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-18.36 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-27.54 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.58 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥20.91 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥12.4 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥21.19 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥26.32 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥53.86 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 74.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.8% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.4% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 56 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 50 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 50 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 46 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 44 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥132m | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥95m | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥119m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥35m | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥42m | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥119m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥169m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | −¥268m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥666m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥341m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥462m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥97m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥298m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.1bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥298m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥1.1bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥632m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥494m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥98m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥946m | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥982m | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.2bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥24m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥649m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥922m | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥334m | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥879m | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.5bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥68m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥215m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-6.36 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-30.54 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.55 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.49 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.48 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥17.46 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥8.73 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.71 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥36.94 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥54.43 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 95.1% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.8% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.8% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 51,509,516 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 36,944,500 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 31,625,800 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,240,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,240,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 12 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 10 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 3 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 2 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 27
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥5m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥103m |
| Cosmetics Beauty And Wellnes Businessreportable segment | employees | at 2023-03-31 | 38 pure |
| Cosmetics Beauty And Wellnes Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.9bn |
| Cosmetics Beauty And Wellnes Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.9bn |
| Cosmetics Beauty And Wellnes Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥5m |
| Cosmetics Beauty And Wellnes Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥64m |
| Sustainable Regenerative Medicine Related Businessreportable segment | employees | at 2023-03-31 | 14 pure |
| Sustainable Regenerative Medicine Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥57m |
| Sustainable Regenerative Medicine Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥57m |
| Sustainable Regenerative Medicine Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥200,000 |
| Sustainable Regenerative Medicine Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥53m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥5m |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | −¥117m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥45m |
| Cosmetics Beauty And Wellnes Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Cosmetics Beauty And Wellnes Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Cosmetics Beauty And Wellnes Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥542m |
| Sustainable Regenerative Medicine Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥450,000 |
| Sustainable Regenerative Medicine Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥450,000 |
| Sustainable Regenerative Medicine Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥95m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | −¥637m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,128
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | 2113883000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | 450000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 2114333000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YearDuration | 2114333000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | -542024000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | -94881000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | -636905000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -44702000 | JPY |
| Operating income | Prior1YearDuration | -681607000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | 10733000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReportableSegmentsMember | 10733000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 10733000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | 5668000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | － | JPY |
| Impairment loss el | Prior1YearDuration_ReportableSegmentsMember | 5668000 | JPY |
| Impairment loss el | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Impairment loss el | Prior1YearDuration | 5668000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | 1934809000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | 57145000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReportableSegmentsMember | 1991954000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 1991954000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | 4522000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | 200000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReportableSegmentsMember | 4722000 | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | -4722000 | JPY |
| Transactions with other segments | CurrentYearDuration | － | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | 1939331000 | JPY |
| Net sales | CurrentYearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | 57345000 | JPY |
| Net sales | CurrentYearDuration_ReportableSegmentsMember | 1996676000 | JPY |
| Net sales | CurrentYearDuration_ReconcilingItemsMember | -4722000 | JPY |
| Net sales | CurrentYearDuration | 1991954000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | -63976000 | JPY |
| Operating income | CurrentYearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | -52940000 | JPY |
| Operating income | CurrentYearDuration_ReportableSegmentsMember | -116916000 | JPY |
| Operating income | CurrentYearDuration_ReconcilingItemsMember | -103438000 | JPY |
| Operating income | CurrentYearDuration | -220355000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | 10733000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E05674-000SustainableRegenerativeMedicineRelatedBusinessReportableSegmentsMember | 2375000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_ReportableSegmentsMember | 13109000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 13109000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E05674-000CosmeticsBeautyAndWellnesBusinessReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |